Abstract:It has been reported that TNFR2 is involved in regulatory T cell induction and myeloid-derived suppressor cell (MDSC) accumulation, two kinds of immunosuppressive cells contributing to tumor immune evasion. Because transmembrane TNF-alpha (tmTNF-alpha) is the primary ligand for TNFR2, we hypothesized that tmTNF-alpha is mainly responsible for the activation of MDSCs. Indeed, we found that tmTNF-alpha, rather than secretory TNF-alpha (sTNF-alpha), activated MDSCs with enhanced suppressive activities, including upregulating arginase-1 and inducible NO synthase transcription, promoting secretion of NO, reactive oxygen species, IL-10, and TGF-beta, and enhancing inhibition of lymphocyte proliferation. This effect of tmTNF-alpha was mediated by TNFR2, as TNFR2 deficiency significantly impaired tmTNF-alpha-induced release of IL-10 and NO and inhibition of T cell proliferation by MDSC supernatant. Furthermore, tmTNF-alpha caused p38 phosphorylation and NF-kappa B activation, whereas inhibition of NF-kappa B or p38 with an inhibitor pyrrolidine dithiocarbamate or SB203580 abrogated tmTNF-alpha-mediated increased suppression of lymphocyte proliferation by MDSCs. Consistently, our in vivo study showed that ectopic expression of uncleavable tmTNF-alpha mutant by 4T1 cells significantly promoted tumor progression and angiogenesis, accompanied with more accumulation of MDSCs and regulatory T cells in the tumor site, increased production of NO, IL-10, and TGF-beta, as well as poor lymphocyte infiltration. In contrast, enforced expression of sTNF-a mutant by 4T1 cells that only released sTNF-alpha without expression of surface tmTNF-alpha markedly reduced MDSC accumulation and induced more lymphocyte infiltration instead, showing obvious tumor regression. Our data suggest that tmTNF-alpha acts as a potent activator of MDSCs via TNFR2 and reveals another novel immunosuppressive effect of this membrane molecule that promotes tumor immune escape.

TMED10 Protein Interferes with Transforming Growth Factor (Tgf)-Β Signaling by Disrupting TGF-β Receptor Complex Formation

TACE-Mediated Ectodomain Shedding of the Type I TGF-b Receptor Downregulates TGF-b Signaling

TACE-Mediated Ectodomain Shedding of the Type I TGF-β Receptor Downregulates TGF-β Signaling

Tmepai, A Transmembrane Tgf-Beta-Inducible Protein, Sequesters Smad Proteins from Active Participation in Tgf-Beta Signaling

Original Protein tyrosine phosphatase PTPN2 regulates TGF- signaling through Smad4 dephosphorylation

Trim30 Alpha Negatively Regulates Tlr-Mediated Nf-Kappa B Activation By Targeting Tab2 And Tab3 For Degradation

TACE activation by MAPK-mediated regulation of cell surface dimerization and TIMP3 association.

TMEPAI, a transmembrane TGF-β-inducible protein, sequesters Smad proteins in TGF-β signaling

Mtmr4 Attenuates Transforming Growth Factor Beta (Tgf Beta) Signaling By Dephosphorylating R-Smads In Endosomes

TMED3 promotes the development of malignant melanoma by targeting CDCA8 and regulating PI3K/Akt pathway

TMED10 Mediates the Trafficking of Insulin-Like Growth Factor 2 along the Secretory Pathway for Myoblast Differentiation.

Negative Regulation of TGF-β Receptor/smad Signal Transduction

Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer

Smad7 Protein Interacts with Receptor-regulated Smads (R-Smads) to Inhibit Transforming Growth Factor-β (TGF-β)/Smad Signaling

The adhesion molecule PECAM-1 enhances the TGF-β-mediated inhibition of T cell function

TLR10 Is a Negative Regulator of Both MyD88-Dependent and -Independent TLR Signaling

Transmembrane TNF-A Promotes Suppressive Activities of Myeloid-Derived Suppressor Cells via TNFR2

Elucidation of Smad Requirement in Transforming Growth Factor-β Type I Receptor-induced Responses

Disruption of the transforming growth factor-β pathway by tolfenamic acid via the ERK MAP kinase pathway.

PPM1A Functions As a Smad Phosphatase to Terminate TGFβ Signaling

TGF-β-induced alternative splicing of TAK1 promotes EMT and drug resistance